We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Galapagos Obtains U.S. Patent Protecting Its Discovery Platform

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Galapagos has announced that it has received a Notice of Allowance of a third US patent related to “High throughput screening of gene function using adenoviral libraries for functional genomics applications.”

Whereas the first two granted US patents claimed the adenoviral library and the method of producing such library, this third patent protects the method of determining the function of a nucleic acid; moreover, it extends the patent life until 2019.

In 2004, the European patent office granted Galapagos a patent with similar claims that remained unchallenged during the opposition period, and in May 2005 Galapagos was granted the corresponding Japanese patent.

This suite of granted patents protects the Company's adenoviral gene knock-down (SilenceSelect®) and gene knock-in (FLeXSelect®) collections, the core of multiple target discovery deals with pharmaceutical and biotech companies as well as patient organizations.

"We are very pleased with this latest Notice of Allowance, as it strengthens the protection of our technologies in functional genomics services into the next decade," said Onno van de Stolpe, CEO of Galapagos.

"It also underscores our strategy to systematically protect inventions made by our innovative scientific teams."

"Our intellectual property position provides us with a unique position in drug target discovery and this translates into income to support our internal drug discovery efforts."